The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Flatiron Health
Research Funding - Lilly
Real-world (rw) clinical outcomes for advanced/metastatic non-small cell lung cancer (aNSCLC) patients (pts) treated with second line (2L) ramucirumab plus docetaxel (R+D) post frontline (1L) platinum based chemotherapy plus immune checkpoint inhibitors (Pt + ICI).
 
Jeffrey Melson Clarke
Consulting or Advisory Role - AstraZeneca; Guardant Health
Speakers' Bureau - Guardant Health; Lilly; Merck
Research Funding - Abbvie; Adaptimmune; Bristol-Myers Squibb; Genentech/Roche; medpacto; Moderna Therapeutics; Spectrum Pharmaceuticals
 
Raina Mathur
Employment - Flatiron Health
Research Funding - Lilly (Inst)
 
Cliff Molife
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Research Funding - Lilly
 
Marta Batus
No Relationships to Disclose
 
Victoria Jennifer Stefaniak
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Katherine B. Winfree
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Shrujal Baxi
No Relationships to Disclose
 
Zhanglin Lin Cui
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
David Lenis
Employment - Flatiron Health
Research Funding - Lilly (Inst)
 
Philip D. Bonomi
Honoraria - AstraZeneca; Biodesix; Bristol-Myers Squibb; Helsinn Therapeutics; Lilly; Merck; pfizer; Roche/Genentech; Trovagene
Consulting or Advisory Role - AstraZeneca; Biodesix; Bristol-Myers Squibb; Helsinn Therapeutics; Lilly; Merck; Merck; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Biodesix (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Five Prime Therapeutics (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst)